| 28.775 0.025 (0.09%) | 05-16 13:51 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.9 | 1-year : | 39.6 |
| Resists | First : | 29.03 | Second : | 33.9 |
| Pivot price | 28.17  |
|||
| Supports | First : | 26.76 |
Second : | 25.36 |
| MAs | MA(5) : | 28.44 |
MA(20) : | 27.73 |
| MA(100) : | 26.71 |
MA(250) : | 27.32 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 80.5 |
D(3) : | 75.2 |
| RSI | RSI(14): 63.1 |
|||
| 52-week | High : | 31.71 | Low : | 23.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SNN ] has closed below upper band by 21.6%. Bollinger Bands are 23% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.79 - 28.94 | 28.94 - 29.08 |
| Low: | 28.1 - 28.25 | 28.25 - 28.4 |
| Close: | 28.51 - 28.75 | 28.75 - 28.98 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Fri, 16 May 2025
Hospital tells family brain-dead Georgia woman must carry fetus to birth because of abortion ban - AP News
Fri, 16 May 2025
Ben Roberts-Smith loses appeal against defamation ruling he committed war crimes in Afghanistan - The Guardian
Thu, 15 May 2025
Ben Roberts-Smith: Top soldier loses war crimes defamation case appeal - BBC
Thu, 15 May 2025
Ben Roberts-Smith loses appeal bid to overturn defamation case loss, signals High Court challenge - Australian Broadcasting Corporation
Thu, 15 May 2025
Pregnant US woman declared brain dead is being kept alive under state abortion law - The Guardian
Thu, 15 May 2025
Stephen A. Smith crashes ESPN set to panic over Celtics beating Knicks - Boston.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 438 (M) |
| Shares Float | 863 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 8 (%) |
| Shares Short | 1,530 (K) |
| Shares Short P.Month | 1,140 (K) |
| EPS | 0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.03 |
| Profit Margin | 7 % |
| Operating Margin | 18.7 % |
| Return on Assets (ttm) | 5.4 % |
| Return on Equity (ttm) | 7.8 % |
| Qtrly Rev. Growth | 6 % |
| Gross Profit (p.s.) | 9.32 |
| Sales Per Share | 13.27 |
| EBITDA (p.s.) | 3.06 |
| Qtrly Earnings Growth | 116.4 % |
| Operating Cash Flow | 987 (M) |
| Levered Free Cash Flow | 565 (M) |
| PE Ratio | 30.65 |
| PEG Ratio | 0 |
| Price to Book value | 4.77 |
| Price to Sales | 2.16 |
| Price to Cash Flow | 12.77 |
| Dividend | 0.46 |
| Forward Dividend | 0 |
| Dividend Yield | 1.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|